• linkedin
  • Increase Font
  • Sharebar

    Sleep duration linked to PCa mortality risk in younger men

    Sleeping less than 7 hours per night is linked to increased risk of prostate cancer mortality in men younger than 65 years of age, but not among their older counterparts, according to a study presented at the American Association for Cancer Research annual meeting in Washington.

    While previous research uncovered a similar association among employed men, this study looks at sleep duration and prostate cancer mortality risk in men regardless of employment status, said lead author Susan M. Gapstur, PhD, MPH, of the American Cancer Society in Atlanta.

    Read: ASCO issues guidance on second-line hormonal Tx in CRPC

    “In a previous analysis that was limited to employed men in the Cancer Prevention Study (CPS)-II, one of the American Cancer Society’s large prospective cohort studies, we found that sleeping 3 to 5 or 6 hours per night was associated with a higher risk of fatal prostate cancer compared to sleeping about 7 hours per night. We found this association only during the first 8 years of study follow-up and in men younger than 65 years of age,” Dr. Gapstur told Urology Times. “The purpose of this study is to expand on the earlier findings from CPS-II, by examining the association between sleep duration and prostate cancer death in a combined analysis of men in CPS-II and in an earlier cohort study, CPS-I, regardless of employment status.”

    The results, she said, support a growing body of evidence that factors associated with circadian rhythm disruption might play a role in prostate carcinogenesis.

    Next: 55% higher risk of PCa death seen in younger men with 3 to 5 hours of sleep

    Lisette Hilton
    Lisette Hilton is a writer in Boca Raton, Fla., who heads up her company, Words Come Alive.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available